HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $2 Price Target

Benzinga · 03/18 11:21
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $2 price target.